Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONITORA STEP1
2024-514313-35-00Phase 4Authorised
- Sponsor
- CHU Saint-Etienne
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by CHU Saint-Etienne. Planned start Sep 2024; status: authorised.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-514313-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514313-35-00.